ERG Co-writes Article Highlighting Challenges of Select Policy Tools Designed to Promote Antibacterial Drug Development

antibacterial resistance

ERG’s Aylin Sertkaya co-wrote a recently published Applied Health Economics and Health Policy article that examines how some policies designed to promote drug development can fall short of that goal. The article, Promoting Antibacterial Drug Development: Select Policies and Challenges, addresses the urgent need to incentivize antibacterial drug development in the face of antibacterial resistance. Aylin worked with researchers from the U.S. Department of Health and Human Services to develop a decision-tree framework that examines the effects of two types of incentives on antibacterial drug company returns. She also helped collect data and analyze the results, ultimately determining that the policies examined under-incentivize early-stage developers and over-incentivize late-stage developers.

Newer Older